Monday, November 16, 2026 Vol. I · No. 4
Business · Via MarketWatch

The FDA declined to approve one of biotech’s most closely watched cancer drugs

Image: MarketWatch

The regulator told Summit Therapeutics that the lung-cancer drug needs to prove it can help people live longer.

This is a brief. The reporting belongs to MarketWatch — read the complete story, with full context and credits, at the source.

Read the full story at MarketWatch ↗

marketwatch.com

More from the Business desk